Commentary|Videos|March 17, 2026

Treating Triple Negative Breast Cancer in the Frontline Setting

Fact checked by: Paige Britt

Frontline antibody-drug conjugates boost progression-free survival in metastatic triple-negative breast cancer, showing early overall survival gains and expanding options.

In an interview with Targeted Oncology, Natalie Berger, MD, hematologist and oncologist at the New York Presbyterian Medical Group, discusses some of the most exciting areas of breast cancer research, including treating triple negative breast cancer in the frontline setting.


Latest CME